Hypoglycaemia is a common side-effect of diabetes therapies, particularly insulin, and imposes a substantial burden on individuals and healthcare systems. Consequently, regulatory approval of newer basal insulin (BI) therapies has relied on demonstration of a balance between achievement of good glycaemic control and less hypoglycaemia. Randomized controlled trials (RCTs) are the gold standard for assessing efficacy and safety, including hypoglycaemia risk, of BIs and are invaluable for obtaining regulatory approval. However, their highly selected patient populations and their conditions lead to results that may not be representative of real-life situations. Real-world evidence (RWE) studies are more representative of clinical practice, but they also have limitations. As such, data both from RCTs and RWE studies provide a fuller picture of the hypoglycaemia risk with BI therapies. However, substantial differences exist in the way hypoglycaemia is reported across these studies, which confounds comparisons of hypoglycaemia frequency among different BIs. This problem is ongoing and persists in recent trials of second-generation BI analogues.
sleep and cause chronic fatigue, with an overall reduction in healthrelated quality of life. [1] [2] [3] The resulting fear of hypoglycaemia may cause some individuals to deliberately maintain undesirable hyperglycaemia to minimize the risk and severity of further hypoglycaemia events. 2 Hyperglycaemia is also an important consideration in the management of individuals with diabetes, with poor glycaemic control being associated with increased risk of micro-and macrovascular complications, cardiovascular (CV) risk and all-cause mortality, 4, 5 as well as being a burden on healthcare resources. 6 The effective use of insulin requires a sensitive balance between achieving and maintaining glycaemic targets while limiting the risk of hypoglycaemia. 1 Consequently, the assessment and regulatory approval of insulins have depended largely on evidence of glycaemic efficacy combined with incremental reductions in therapy-induced hypoglycaemia, utilizing data commonly derived from randomized controlled trials (RCTs). 7 It is also important to determine whether the hypoglycaemia reductions observed in the tightly regulated conditions observed in RCTs are also observed in real-life clinical practice, in which patient populations are more diverse and clinical monitoring and support is less extensive compared with an RCT. 8 The more diverse patient populations, less rigorous protocols and less intensive patient followup of real-world evidence (RWE) studies 9 may be more representative of clinical practice. 10, 11 As such, although the reporting of hypoglycaemia events may be less accurate in RWE studies, observational studies of electronic health records, medical claims and billing data and registries, or prospective RWE studies such as crosssectional surveys are needed to provide a complementary source of information concerning the frequency of hypoglycaemia associated with insulins.
The disparities in definitions, methods of assessment and reporting of hypoglycaemia across RCTs and RWE studies, combined with the differences in trial designs, analyses and populations, present significant challenges when comparing different insulin molecules and formulations. These issues can obfuscate the true differences in the safety of glucose-lowering therapies and may explain the observed inconsistencies across various regulatory and advisory guidelines.
Differences in reporting of BI therapies in the context of hypoglycaemia have been an ongoing challenge, with great variability among early trials of BIs; however, considerable diversity in reporting still exists in the most recent trials of second-generation BI analogues, which precludes true comparisons of their safety across trials.
Although second-generation BI analogues have demonstrated lower rates of hypoglycaemia as compared with first-generation BIs, [12] [13] [14] the risk of hypoglycaemia has not yet been eradicated and it is therefore important to facilitate interpretation of efficacy and safety among
BIs. In addition, as further advances in BI therapies occur, standardization across trials of these newer therapies and technologies would be beneficial, to facilitate interpretation of their hypoglycaemia risk profiles.
Improved understanding of the differences in reporting of hypoglycaemia is required and, ultimately, greater standardization concerning the way hypoglycaemia is defined, measured and analysed would greatly aid the interpretation of the safety of BI therapies across trials. The present review describes the differences in the way hypoglycaemia has been defined, measured and reported in both RCTs and RWE studies, with a focus on the most recent studies of second-generation BIs. Potential explanations for the diversity observed across studies are discussed. Nocturnal and daytime hypoglycaemia, both non-severe and severe, in individuals with type 1 and type 2 diabetes (T1DM and T2DM) are explored.
| DIVERSITY OF HYPOGLYCAEMIA ASSESSMENT AND REPORTING IN RANDOMIZED CONTROLLED TRIALS
Until the advent of treat-to-target trial designs, insulin titration in clinical trials was undertaken largely at the discretion of the investigator. 15 The first treat-to-target trial was conducted in 2003; this trial design used a pre-specified algorithm to titrate either insulin glargine 100 U/mL (Gla-100) or isophane insulin (neutral protamine Hagedorn
[NPH] insulin) to achieve and maintain a target fasting plasma glucose of 5.5 mmol/L (100 mg/dL). 16 In this way, treat-to-target trials highlighted the differences in factors such as hypoglycaemia, as blood glucose levels are driven closer to euglycaemia. 17 To demonstrate the diversity in reporting of hypoglycaemia across RCTs, the present review focuses on two treat-to-target trial programmes of second-generation BI analogues, namely, the BEGIN trials, which compared insulin degludec (IDeg) with insulin glargine 100 U/mL (Gla-100), [18] [19] [20] [21] [22] [23] [24] [25] [26] and the EDITION trials, in which insulin glargine 300 U/mL (Gla-300) and Gla-100 were compared. Some of the older treat-to-target trials of first-generation BI analogues, 12, [27] [28] [29] [30] [31] Gla-100 and insulin detemir (IDet) vs NPH insulin have been included for comparison. 16, [32] [33] [34] The BEGIN and EDITION trials ( Table 1 and Table S1 ) shared certain common design features. For example, both trials were randomized, open-label and treat-to-target trials. However, there were key differences between the trials, such as the starting dose of insulin, titration algorithms, targets for self-monitored blood glucose (SMBG) and hypoglycaemia definitions. These differences are examined in greater detail in the following sections.
| Eligibility criteria
Variability in inclusion and exclusion criteria can influence hypoglycaemia risk results, as various baseline characteristics can be associated with hypoglycaemia. 35 The BEGIN and EDITION trials attempted to account for differing hypoglycaemia risk factors by grouping trial populations according to the nature of previous antihyperglycaemic therapy (eg, BEGIN basal-bolus type 2, 18 BEGIN Low Volume 20 and the EDITION 1, 2 and 3 trials), [27] [28] [29] or by racial background (eg, the BEGIN Asia trial 21 13 populations, which contribute to comparison of BIs among participants with a range of baseline characteristics, but the post hoc nature of these studies is a significant limitation.
| Hypoglycaemia classification and glycaemic thresholds
Various advisory groups have proposed definitions of hypoglycaemia to standardize the way it is reported. However, important heterogeneity exists among these guidelines ( Table 2) , which has contributed to differences in the way hypoglycaemia has been reported across clinical trials. 7 A meta-analysis of trials included in the Canadian Agency for Drugs and Technologies in Health Reports examined the way hypoglycaemia was reported in trials of glucose-lowering drugs, including oral antihyperglycaemic drugs, fast-acting insulins and BIs. 36 This revealed that definitions of hypoglycaemia were included in only 60% of these trials, 36 and few of these definitions followed American
Diabetes Association (ADA) 37 and European Medicines Agency (EMA) 38 recommendations for definition of hypoglycaemia as blood glucose (BG) of ≤3.9 mmol/L (≤70 mg/dL), or <3.1 mmol/L (<56 mg/dL), which was recommended by the EMA prior to 2012. 36 The differences in BG thresholds for non-severe hypoglycaemia can be seen in the examples of treat-to-target trials shown in non-severe hypoglycaemia, but the glycaemic threshold no greater than 3.9 mmol/L (≤70 mg/dL), now designated as an "alert level," has been considered for some time to be indicative of non-severe hypoglycaemia. 39, 40 Ideally, in line with recent guidelines, both thresholds should be reported routinely. 39, 40 Consistency in the definitions of non-severe and severe hypoglycaemia episodes in clinical trials is not just desirable, it is essential in facilitating interpretations of the frequency of hypoglycaemia among different treatment regimens. This should be possible with adoption of the revised definitions of hypoglycaemia that have achieved international consensus. 39, 40 For instance, definitions of severe hypoglycaemia varied considerably before the initial ADA working group guidelines were published in 2002, [41] [42] [43] including definitions in the original treat-to-target trial. 16 However, severe hypoglycaemia has typically been defined across all trials as an event requiring external assistance to administer oral carbohydrate or parenteral therapy in the form of intramuscular glucagon or intravenous dextrose, regardless of whether BG has been measured, as per ADA recommendations. 44 
| Duration of follow-up
The duration of patient follow-up in RCTs of BIs has varied widely, ranging from 4 weeks 45,46 to 2 years, 33 and is apparent in the treatto-target trials shown in Table 1 and Table S1 . Variation in trial length is an important factor in the quantification of event frequency. Longer trials increase the probability of observing hypoglycaemia events, which is particularly important for those classified as severe, thereby mitigating the potential for false negative results and enhancing the statistical power to detect differences among BIs in therapy-induced hypoglycaemia, assuming that the effect sizes remain constant. If participants withdraw from a study because of morbidity associated with severe hypoglycaemia, the risk of exposure to hypoglycaemia is modified by this attrition, particularly if these are individuals with the highest risk of hypoglycaemia. As such, the proportion of participants experiencing at least one hypoglycaemia event may be more relevant in shorter trials, as this measure would be greatly influenced by the progressive withdrawal of individual participants during a prolonged followup period. Additionally, in trials that use retrospective patient recall of [48] [49] [50] [51] [52] However, participants often maintain BI doses during these extension periods, and, in efforts to avoid hypoglycaemia, they may be less effective in titrating their dose and achieving glycaemic targets.
| Clock time definitions
Nocturnal hypoglycaemia has negative effects on quality of life 3 and can incur major economic costs. 53 In clinical trials, nocturnal hypoglycaemia is often defined by its occurrence during a pre-determined clock time,
which differs among studies. The longer the period selected to define EDITION original definition, 12:00 AM to 05:59 AM vs the expanded definition, 22:00 to pre-breakfast SMPG measurement). 56, 57 Both of these analyses highlighted that a large number of hypoglycaemia events occurred within the pre-breakfast time period. 56, 57 As such, the commonly used nocturnal window of 12:00 AM to 6:00 AM may lead to underestimation of the clinically relevant impact of nocturnal hypoglycaemia. Furthermore, in meta-analysis of the BEGIN trials, the hypoglycaemia risk benefit of IDeg vs Gla-100 was significant for all comparisons, with the exception the 00:01 to 07:59 h nocturnal interval. 56,57
| Titration protocols
As discussed earlier, the advent of the treat-to-target trial design facilitated comparison of safety profiles, including hypoglycaemia, among
BIs. Nevertheless, differences in various clinical trials using the treatto-target design are apparent ( Table 1 and Table S1 ). One such example is a design in which different target BG concentrations have been used. While no correlation between target BG and HbA1c has been shown, 15 adopting a lower target BG may be more likely to increase both the incidence and prevalence of hypoglycaemia events, which may enhance the prospect of observing statistically significant differences among treatments.
The frequency of insulin dose adjustments and the incremental changes during titration have also differed among trials. Although the BEGIN and EDITION trials typically used the same titration algorithm for control and experimental insulins within each trial, the BEGIN trials utilized a titration algorithm with larger dose adjustments than that utilized in the EDITION trials (Figure 1 ), which may have affected the incidence and prevalence of hypoglycaemia events during the titration period of the former. 12 . Algorithms shown were taken from the original treat-to-target trial (Gla-100 vs NPH), 16 IDet vs NPH, 32 the EDITION 1, 2 and 3 trials (Gla-300 vs Gla-100), [27] [28] [29] and the BEGIN Once Asia and BEGIN Flex trials (IDeg vs Gla-100). 21, 22 Dose adjustments were made based on the median fasting SMBG value of the previous three consecutive days (or previous two consecutive days for the original treat-to-target trial), unless otherwise stated. a Dose decreased unless there was an obvious reason for the low BG value; b for doses >40 U, dose was reduced by 10%; c for doses >40 U, dose was reduced by 5%; d if SMBG was <3.3 mmol/L (<60 mg/dL), insulin dose could be reduced by ≥3 units, at the investigators discretion; e for doses >45 U, a 10% reduction was recommended; f for doses >45 U, a 5% reduction was recommended translated to lower hypoglycaemia risk throughout the period of treatment. 13 Extension periods examine efficacy and safety over a prolonged period of exposure to therapies and are often more representative of an RWE clinical setting; the follow-up is less rigorous, and participants are less likely to conform to the closely controlled treatment protocols of clinical trials. Consequently, the apparent hypoglycaemia risk benefits that are observed during the on-study period in RCTs may be less pronounced in the extension period. For instance, 12-month data from the EDITION trials showed that HbA1c levels in the Gla-100 group increased slightly in the 6-month extension period, which coincided with slight attenuation of the hypoglycaemia benefit of Gla-300 over Gla-100. 59 A possible explanation may be that insulin dose was titrated less rigorously during the extension period, thereby reducing the overall risk of hypoglycaemia, but at the cost of achieving less stringent glycaemic control. In the BEGIN Once Long trial, HbA1c levels also rose in the extension period, with similar increments being observed for IDeg and Gla-100; however, the hypoglycaemia risk benefit seen with IDeg vs Gla-100 improved during this period. 60 CGM has several limitations. Initially, there were concerns regarding its accuracy, with early devices having a variability of more than 20%; variability has since improved to approximately 10%. 62 Furthermore, aside from sensor issues, for example, occasional sensor failure and the requirement for regular recalibration with SMBG, consensus is currently lacking as to which of the glycaemic parameters derived from CGM should be reported. [63] [64] [65] The absence of system comparability, combined with data communication systems that are constantly evolving, also prevent comparisons between different CGM trials. 65 CGM has been used in RCTs to compare Gla-100 and IDet, 66 and IDeg, in combination with insulin aspart, 67 and Gla-300; 68 Table S1 ). However, sometimes only one analysis of between-treatment differences has been reported, often the hypoglycaemia event rate ratios, 54, 55, 69, 70 which hinders assessment of the consistency of results across trials. For instance, the BEGIN trials [18] [19] [20] [21] [22] [23] [24] [25] [26] focused on rate ratios between BIs, whereas the EDITION studies 12,27-31 presented both the rate ratio and relative risks.
| Hypoglycaemia measurements
The methods used to assess these outcomes and adjustments for confounding factors can also vary across trials. For instance, the BEGIN studies employed a negative binomial regression model to assess the rates of hypoglycaemia, with treatment, antihyperglycaemic therapy at screening, gender and geographical region as fixed factors, and with age as a covariate, [18] [19] [20] [21] [22] [23] [24] [25] [26] whereas the EDITION trials utilized an overdispersed Poisson regression model. 12, 14, [27] [28] [29] [30] [31] However, the EDITION studies also analysed the number of individuals experiencing more than one hypoglycaemia event, a binary outcome, for which a Cochran-Mantel-Haenszel method, a statistical method that tests the association of a treatment with a specific binary outcome, was used to assess between-treatment differences, stratified by HbA1c at screening and by geographical region. 12,27-31 The variation in analyses described above may influence outcomes and, therefore, standardization in statistical testing of hypoglycaemia endpoints should be applied to trials of BIs.
| HYPOGLYCAEMIA ASSESSMENT IN RWE STUDIES

| RCTs versus real-life clinical practice
RCTs are considered to be the "gold standard" and are essential for demonstrating the efficacy and safety of new therapies. 71 However, inherent limitations in their design may lead to underestimation of rates of hypoglycaemia. 72 For example, RCTs may exclude participants with very high HbA1c levels or those with renal impairment, 8 both of whom are associated with increased risk of hypoglycaemia. 35 Clinical trial participants are often a more engaged and informed subpopulation of individuals with diabetes and, hence, are more likely to adhere to treatment and to accept advice on diabetes self-care. 8 In addition, clinical monitoring and support are much more extensive during an RCT compared with that received within routine clinical practice.
While this may ensure more efficient capture of hypoglycaemia events, it limits the extrapolation of data on hypoglycaemia occurrence from clinical trials to influence real-life practice. 8 Currently, the hypoglycaemia definitions and glycaemic threshold values used in regulatory guidelines reflect consensus guidelines from working groups; however, the evidence from RWE studies that influence these decisions is limited. Consequently, the rates of hypoglycaemia reported in these trials may not be representative of real-life. For example, a recent systematic review showed that RWE studies frequently report higher rates of hypoglycaemia than those reported in RCTs, particularly when the primary focus of the study was to investigate hypoglycaemia. 72 High-risk populations, such as children, individuals over 70 years of age, pregnant women, individuals with renal impairment or with impaired awareness of hypoglycaemia (IAH), and patients with a history of previous severe hypoglycaemia are often excluded from RCTs.
However, it is these vulnerable populations that may experience the greatest benefit from new therapies that confer good glycaemic control with a lower hypoglycaemia risk profile. Attempts to address knowledge gaps in previous RCTs concerning these vulnerable or high-risk populations have been made by specifically recruiting participants from high-risk populations such as children, 43, 54, 73 pregnant women, [74] [75] [76] older individuals 77 and individuals with specific risk factors for hypoglycaemia. 78, 79 However, these trials all involved a high level of participant follow-up and employed strict protocols for titration; as such, they may not represent real-life clinical experience. (CPRD). 82 The effectiveness and safety of Gla-100 or IDeg have been investigated in observational retrospective studies of such databases, such as the DELIVER [83] [84] [85] and ReFLECT studies. 86 Additionally, the LIGHTNING and CONFIRM trials compared rates of hypoglycaemia between Gla-300 and IDeg reported in real-world data from electronic healthcare records. 87, 88 Given the less stringent protocols that are often associated with RWE studies, the diversity in hypoglycaemia reporting in these studies is likely to be even greater than that in RCTs. Hypoglycaemia docu- Furthermore, given that many observational studies are less resourceintensive, the capacity for long periods of follow-up is much greater than that for many RCTs. One such example is the UK Prospective
| Real-world evidence studies
Diabetes Study (UKPDS), which examined the frequency of selfreported hypoglycaemia of differing severities in individuals with T1DM and T2DM over a follow-up period of 10 years. 93 This study highlighted the observation that rates of hypoglycaemia in unselected participant populations were often higher than those reported in RCTs. 93 RWE studies are also able to demonstrate the epidemiology and economic burden associated with hypoglycaemia. For example, the global Hypoglycaemia Assessment Tool (HAT) study estimated the frequency and severity of hypoglycaemia worldwide and demonstrated that hypoglycaemia rates were very high, with large variations observed between geographical regions. 94 The HAT study also showed that prospective recording demonstrated much higher rates of hypoglycaemia than retrospective assessment. Meneghini et al. 95 reported results from a retrospective observational study which highlighted that, compared with absence of hypoglycaemia, severe hypoglycaemia was associated with significantly lower health-related quality-of-life (P < .001), reduced work productivity (P = .004), impaired ability to perform regular daily activities (P < .001), greater healthcare-resource utilization and increased total healthcare costs (P < .001). 95 The DELIVER-2 study provided valuable insight into cost-effectiveness and healthcare resource utilization associated with hypoglycaemia risk in individuals receiving BIs. 83 Prospective observational studies offer an alternative approach to retrospective observational studies of electronic health records and registries. One example is the DUNE study, which assessed the association between achieving a pre-determined HbA1c target and the frequency of hypoglycaemia in a real-life setting in individuals with T2DM. 96 The prospective design of the study enabled the use of three hypoglycaemia categories for reporting events: severe (any event requiring assistance); non-severe (any event associated with typical symptoms, regardless of BG measurement); and documented [any event with a BG measurement either ≤3.9 mmol/L (≤70 mg/dL) or <3.0 mmol/L (<54 mg/dL)]. 96 This enabled more rigorous definitions of hypoglycaemia to be applied while still utilizing a real-life clinical practice setting. Evidence from the DUNE study highlighted the observation that achievement of glycaemic targets with BIs was poor (~30%) in a real-life setting, possibly because of suboptimal titration of insulin. 96 Interestingly, the DUNE study also showed that HbA1c targets were more likely to be achieved in patients who experienced more hypoglycaemia events. 96 39, 40 Additionally, studies increasingly use a standard window of 12:00 to 6:00 AM to define nocturnal hypoglycaemia.
Consensus guidelines concerning the way to measure and report hypoglycaemia events detected by CGM would be beneficial and can be feasibly achieved, but they will require large trials investigating the use of CGM as SMBG to detect hypoglycaemia, which would enable evidence-based opinion concerning the utility of CGM devices and the optimal glycaemic parameters for reporting in CGM-based studies.
However, standardization may not be easily achieved with certain aspects of study design. Inclusion criteria in RCTs may vary, to investigate efficacy and safety in specific populations such as individuals with T2DM undergoing basal-bolus regimens. While this helps to eliminate potential confounders, it also makes interpretation among trials difficult. One approach may be to reduce the number of inclusion criteria and to include more varied populations, similar to those experienced in clinical practice; however, this would require more complex statistical methods to account for potential bias.
While the treat-to-target trial design has facilitated comparisons between BIs for factors other than glycaemic control, including hypoglycaemia, substantial variation in glycaemic targets among trials remains common. Given that the ADA recommends different targets in vulnerable populations, such as children or frail elderly individuals, 37 several standardized glycaemic targets may be required for different age groups or for patients at high risk of hypoglycaemia.
The variation observed in titration algorithms among different treatto-target trials may also be a consequence of the different pharmaco- The present review has some limitations. It was not a systematic meta-analysis and, as such, some recent trials of second-generation Bis may have been omitted. In addition, this review focuses on a small subset of diabetes therapies, specifically second-generation BI analogues. However, the noted disparities in hypoglycaemia reporting are also apparent in trials of various antihyperglycaemic drugs.
In conclusion, hypoglycaemia risk profiles of BIs remain important factors in choosing between therapies, but the current diversity in the way hypoglycaemia is reported across RCTs and RWE studies prevents comparisons among studies. The development and application of consensus guidelines denoting the way hypoglycaemia should be defined and reported would contribute to future study design in a way that facilitates interpretation of hypoglycaemia risk profiles among BIs across studies.
